Has Janell Verkaden received payments from drug or device companies?

Yes. Drug and device makers reported $19,022 in general payments to Janell Verkaden across 698 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Janell Verkaden did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Janell Verkaden come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Janell Verkaden

Oncology · Ormond Beach, FLNPI 1871543520

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $15,126 of the $19,022 with a category attached, or 79.5%. 60 manufacturers reported payments, led by Novartis at 27.0% of the total. 2025 is the largest year on record at $5,347, 3.1 times the $1,751 reported in 2021. Among oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,022in general payments, 2019–2025

Across 698 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$5K
AstraZeneca$1K
Merck$951
Johnson & Johnson$914
Seagen Inc.$620
Incyte Corporation$577
plus $9K from 54 others

What the payments were for

Food & beverage$15,12680%
Education$2982%
Other$3,59819%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	131	$5,127
AstraZeneca(2 entities)	37	$1,326
Merck	43	$951
Johnson & Johnson(2 entities)	39	$914
Seagen Inc.	24	$620
Incyte Corporation	25	$577
Pfizer	24	$446
Sobi, Inc	15	$446
Lilly USA, LLC	20	$435
Takeda Pharmaceuticals U.S.A., Inc.	13	$397
Gilead	18	$387
Stemline Therapeutics Inc.	11	$345
Novo Nordisk	3	$342
Eisai Inc.	18	$332
Bayer	15	$328
Daiichi Sankyo Inc.	18	$328
Genentech USA, Inc.	13	$314
Bristol Myers Squibb	14	$298
Sanofi	13	$277
AbbVie	12	$260
Regeneron Healthcare Solutions, Inc.	12	$249
GSK	12	$245
Apellis Pharmaceuticals, Inc.	4	$237
E.r. Squibb & Sons, L.L.C.	12	$225
Sanofi-aventis U.S. LLC	2	$206
Exelixis Inc.	10	$196
Amgen	11	$188
Astellas Pharma US Inc	10	$183
Tersera Therapeutics LLC	8	$180
Pharmacosmos Therapeutics Inc.	8	$164
Taiho Oncology, Inc.	8	$158
Ipsen Biopharmaceuticals, Inc	9	$153
Mirati Therapeutics, Inc.	6	$131
Array Biopharma Inc	7	$126
EMD Serono, Inc.	6	$112
G1 Therapeutics, Inc.	6	$110
Servier Pharmaceuticals LLC	5	$106
Silk Road Medical, Inc.	1	$104
Dendreon Pharmaceuticals LLC	4	$103
Solventum Corporation	1	$100
Alkermes, Inc.	1	$100
Esperion Therapeutics, Inc.	1	$96
Boehringer Ingelheim	4	$89
Jazz Pharmaceuticals Inc.	5	$84
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$76
Ceribell, Inc.	1	$75
ADC Therapeutics America, Inc.	4	$69
CTI Biopharma Corp.	4	$65
Philips North America LLC	1	$58
Pharmacyclics LLC, An Abbvie Company	2	$54
Legend Biotech USA Inc.	2	$53
Beone Medicines USA, Inc.	2	$53
Karyopharm Therapeutics Inc.	2	$37
Octapharma USA, Inc.	2	$37
Delcath Systems	1	$34
Puma Biotechnology, Inc.	2	$33
Novocure Inc.	2	$33
AVEO Pharmaceuticals, Inc.	2	$32
Alnylam Pharmaceuticals Inc.	1	$28
Deciphera Pharmaceuticals Inc.	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Strensiq$267
ENROUTE Transcarotid Neuroprotection System$207
TZIELD$206
XARELTO$135
Orserdu$125
PADCEV$121
Empaveli$120
Vonjo$108
ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$104
ENROUTE Transcarotid Stent$104
Wegovy$101
V.A.C. VERAFLO$100
V.A.C. ULTA$100

How this compares

$19,022 in reported general payments places this provider in the 90th percentile of 24 oncology providers in Florida.

See all oncology providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Megestrol Acetate	12	$783
Hydroxyurea	11	$494
Acyclovir	17	$260
Ondansetron OdtOndansetron	15	$247
Potassium Chloride	14	$188
Levofloxacin	20	$172
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	18	$170
Levothyroxine Sodium	20	$128

Paid to pharmacies, not to this prescriber.

Other oncology in Ormond Beach

Sara BeelerTampa$337K
Michelle RampersadSebring$34K
Kimberly TopeTampa$16K
Aaron DohenySt Petersburg$14K
Naima Vera-SommersTampa$11K
Amber AlbaughLecanto$9K
Natalie GessnerClearwater$8K
Melissa BlandfordHudson$6K
Glenda KaminskiLakeland$5K
Lee PavelBonita Springs$5K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →